Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
EW

EW - Edwards Lifesciences Corp Stock Price, Fair Value and News

87.73USD+0.11 (+0.13%)Market Closed
Watchlist

Market Summary

USD87.73+0.11
Market Closed
0.13%

EW Alerts

  • 7 major insider sales recently.

EW Stock Price

View Fullscreen

EW RSI Chart

EW Valuation

Market Cap

52.8B

Price/Earnings (Trailing)

37.64

Price/Sales (Trailing)

8.78

EV/EBITDA

29.22

Price/Free Cashflow

82.07

EW Price/Sales (Trailing)

EW Profitability

EBT Margin

26.61%

Return on Equity

20.86%

Return on Assets

14.97%

Free Cashflow Yield

1.22%

EW Fundamentals

EW Revenue

Revenue (TTM)

6.0B

Rev. Growth (Yr)

13.78%

Rev. Growth (Qtr)

3.59%

EW Earnings

Earnings (TTM)

1.4B

Earnings Growth (Yr)

-6.95%

Earnings Growth (Qtr)

-3.69%

Breaking Down EW Revenue

Last 7 days

1.3%

Last 30 days

16.3%

Last 90 days

28.7%

Trailing 12 Months

11.5%

How does EW drawdown profile look like?

EW Financial Health

Current Ratio

3.38

Debt/Equity

0.09

Debt/Cashflow

1.5

EW Investor Care

Buy Backs (1Y)

1.15%

Diluted EPS (TTM)

2.3

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20235.5B5.7B5.8B6.0B
20225.4B5.4B5.4B5.4B
20214.5B4.9B5.1B5.2B
20204.5B4.3B4.4B4.4B
20193.8B4.0B4.2B4.3B
20183.4B3.5B3.6B3.7B
20173.1B3.2B3.3B3.4B
20162.6B2.7B2.9B3.0B
20152.4B2.4B2.4B2.5B
20142.1B2.1B2.2B2.3B
20131.9B2.0B2.0B2.0B
20121.7B1.8B1.8B1.9B
20111.5B1.6B1.6B1.7B
20101.3B1.4B1.4B1.4B
20091.3B1.3B1.3B1.3B
20080001.2B

Tracking the Latest Insider Buys and Sells of Edwards Lifesciences Corp

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 21, 2024
chopra daveen
acquired
414,797
59.2567
7,000
cvp, tmtt
Feb 21, 2024
chopra daveen
sold
-711,272
86.7405
-8,200
cvp, tmtt
Feb 18, 2024
lippis daniel j.
sold (taxes)
-16,186
86.1
-188
cvp, japac
Feb 17, 2024
lippis daniel j.
sold (taxes)
-12,915
86.1
-150
cvp, japac
Feb 16, 2024
wood larry l
sold (taxes)
-27,274
86.04
-317
global president tavr & surg
Feb 16, 2024
lippis daniel j.
sold (taxes)
-17,810
86.04
-207
cvp, japac
Feb 16, 2024
ullem scott b.
sold (taxes)
-14,971
86.04
-174
cvp, chief financial officer
Feb 15, 2024
szyman catherine m.
acquired
992,250
36.75
27,000
cvp, critical care
Feb 15, 2024
szyman catherine m.
sold
-2,311,650
85.6168
-27,000
cvp, critical care
Feb 13, 2024
bobo donald e jr
acquired
404,250
36.75
11,000
cvp,strategy/corp development

1–10 of 50

Which funds bought or sold EW recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 21, 2024
Raleigh Capital Management Inc.
new
-
2,288
2,288
-%
Feb 21, 2024
V-Square Quantitative Management LLC
added
31.59
260,728
842,334
0.15%
Feb 20, 2024
GLOBALT Investments LLC / GA
new
-
944,509
944,509
0.04%
Feb 20, 2024
Clarity Capital Partners LLC
new
-
433,558
433,558
0.30%
Feb 20, 2024
Able Wealth Management LLC
new
-
6,253
6,253
0.01%
Feb 20, 2024
EVENTIDE ASSET MANAGEMENT, LLC
reduced
-31.5
-166,967
511,561
0.01%
Feb 20, 2024
Vancity Investment Management Ltd
reduced
-64.28
-4,482,000
2,903,000
0.42%
Feb 20, 2024
Quarry LP
reduced
-48.72
-40,202
52,079
0.01%
Feb 16, 2024
Aspect Partners, LLC
new
-
915
915
-%
Feb 16, 2024
Sanibel Captiva Trust Company, Inc.
new
-
591,700
591,700
0.02%

1–10 of 46

Are Funds Buying or Selling EW?

Are funds buying EW calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own EW
No. of Funds

Unveiling Edwards Lifesciences Corp's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
8.63%
52,362,913
SC 13G/A
Jan 25, 2024
blackrock inc.
8.6%
52,171,889
SC 13G/A
Feb 09, 2023
vanguard group inc
8.34%
51,559,391
SC 13G/A
Feb 07, 2023
blackrock inc.
8.6%
53,060,508
SC 13G/A
Feb 09, 2022
vanguard group inc
7.86%
49,076,649
SC 13G/A
Feb 03, 2022
blackrock inc.
9.1%
57,040,983
SC 13G/A
Feb 10, 2021
vanguard group inc
7.76%
48,347,685
SC 13G/A
Jan 29, 2021
blackrock inc.
9.4%
58,596,560
SC 13G/A
Feb 12, 2020
vanguard group inc
7.79%
16,261,702
SC 13G/A
Feb 05, 2020
blackrock inc.
8.7%
18,200,799
SC 13G/A

Recent SEC filings of Edwards Lifesciences Corp

View All Filings
Date Filed Form Type Document
Feb 23, 2024
144
Notice of Insider Sale Intent
Feb 23, 2024
4
Insider Trading
Feb 23, 2024
4
Insider Trading
Feb 21, 2024
144
Notice of Insider Sale Intent
Feb 21, 2024
4
Insider Trading
Feb 20, 2024
4
Insider Trading
Feb 16, 2024
4
Insider Trading
Feb 16, 2024
4
Insider Trading
Feb 15, 2024
144
Notice of Insider Sale Intent
Feb 15, 2024
4
Insider Trading

What is the Fair Value of EW?

Loading...
Disclaimer: Conduct thorough research and seek guidance from a certified financial advisor prior to finalizing any investment choices.

Peers (Alternatives to Edwards Lifesciences Corp)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
207.9B
40.1B
0.08% 5.41%
36.32
5.18
-8.12% -17.45%
71.1B
19.5B
1.90% -2.48%
56.63
3.65
4.02% -22.04%
24.3B
3.8B
13.67% -2.23%
66.92
6.38
-1.48% -28.97%
21.6B
14.9B
3.05% 1.38%
8.13
1.45
2.01% 209.17%
MID-CAP
10.4B
12.7B
2.56% -12.12%
23.32
0.82
0.68% -30.25%
9.9B
2.7B
6.89% -27.73%
-15.56
3.71
-4.68% 82.43%
9.3B
3.5B
8.76% 25.90%
32.8
2.68
4.97% 18.89%
7.2B
3.9B
-8.15% -6.44%
-32.81
1.83
-2.62% 73.16%
3.5B
342.6M
-1.40% 20.18%
-288.8
10.11
42.19% 84.12%
2.7B
6.6B
-4.32% -4.67%
13.36
0.41
2.61% 0.52%
SMALL-CAP
1.0B
3.1B
8.08% -63.68%
-2.4
0.33
7.95% -543.98%
380.2M
163.3M
8.18% -20.52%
-15.47
2.33
7.14% -56.09%
231.2M
329.5M
3.17% -52.24%
-16.38
0.7
0.49% 64.22%
69.6M
50.3M
4.50% -30.54%
-4.59
1.38
3.23% 20.81%
4.5M
3.7M
-15.66% 215.09%
-0.36
1.19
5.77% 8.23%

Edwards Lifesciences Corp News

Latest updates
MarketBeat13 hours ago
Investor's Business Daily07 Feb 202408:00 am

Edwards Lifesciences Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue3.6%1,5341,4811,5301,4601,3481,3191,3741,3411,3301,3101,3761,2171,1921,1419251,1291,1741,0941,087993978
Gross Profit4.1%1,1771,1311,1871,1301,0901,0651,1051,0421,0209991,042923895860687864888802783761743
  S&GA Expenses9.2%480440469436411377409370424364375331339307275308347306309280288
  R&D Expenses-0.1%270270270261232234251229233238225207196196182187194196192171163
EBITDA Margin-5.0%0.30*0.31*0.31*0.34*0.36*0.34*0.34*0.36*0.35*0.36*0.36*0.24*---------
Interest Expenses-100.0%-15.009.009.0011.007.001.001.0020.00-0.80-1.000.009.001.002.005.0014.003.002.002.0030.00
Income Taxes-6.5%52.0056.0033.0058.0061.0064.0058.0063.0041.0051.0056.0051.0047.0039.00-46.3054.0035.0027.0029.0028.00-77.90
Earnings Before Taxes-4.0%422439339399459407465436376391546389356364-168365316302271278-1.80
EBT Margin-5.3%0.27*0.28*0.28*0.31*0.33*0.31*0.31*0.33*0.33*0.33*0.34*0.21*---------
Net Income-3.7%371385306341398344406374335340490338310325-1213112802752422507.00
Net Income Margin-5.0%0.23*0.25*0.25*0.27*0.28*0.27*0.27*0.29*0.29*0.29*0.30*0.19*---------
Free Cashflow-86.4%48.00356-14.30253214250289221284471457195---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-0.1%9,3639,3719,0048,6518,2938,6388,4258,4208,5038,1607,6627,2147,2376,8016,4246,0766,4885,9665,5745,4695,324
  Current Assets-0.8%4,0364,0683,6473,2573,0963,5143,2633,2413,1813,5163,3233,0693,0912,9802,6902,5082,9842,7402,3552,3692,287
    Cash Equivalents-18.6%1,1481,4101,0438737691,2521,2031,0358671,5201,3261,1911,1831,0309096681,1841,187727709716
  Inventory13.2%1,1681,032980914876758740731727738760768802773735662641611625631607
  Net PPE4.1%1,7491,6811,6621,6461,6331,5661,5601,5521,5471,4651,4461,4181,3951,2761,1961,1011,060974931892868
  Goodwill-3.4%1,2541,2971,3001,3081,1641,1591,1641,1661,1681,1701,1721,1711,1731,1701,1681,1661,1681,1571,1741,1031,112
Liabilities0.0%2,6442,6442,5582,5892,4862,4202,4822,5752,6672,6192,6342,6482,663--------
  Current Liabilities-3.5%1,1951,2391,1571,0821,0229189699501,032967886799894846873747902776697647877
  Long Term Debt-100.0%-597597597596596596596596596595595595595595595594594594594594
    LT Debt, Current----------------------
    LT Debt, Non Current0.0%597597597597596596596596596596595595595595595595594594594594594
Shareholder's Equity0.9%6,7196,6586,4476,0625,8076,2185,9445,8455,8365,5415,1334,6584,5744,2103,8393,9014,1483,8153,5003,4483,140
  Retained Earnings4.3%8,9928,6238,2387,9317,5907,1926,8486,4426,0685,7335,3934,9034,5654,2563,9304,0523,7423,4613,1872,9442,695
  Additional Paid-In Capital2.9%2,2742,2112,1462,0491,9691,9151,8531,7691,7001,6431,5791,4971,4381,3821,3241,6761,6231,5701,5121,4491,384
Accumulated Depreciation-----750---655---599---512---455
Shares Outstanding-0.9%601607608606608621622622624624622623---------
Minority Interest-0.3%69.0070.0071.0084.00-----------------
Float-------58,454---64,028---42,641---34,109--
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-66.8%13741234.003142833103322933745325263014002162312074034373412.00293
  Share Based Compensation-6.4%31.0033.0037.0039.0028.0030.0036.0032.0024.0027.0030.0028.0021.0023.0025.0024.0018.0020.0022.0021.0016.00
Cashflow From Investing-84.2%14.0089.0070.001.0095.00-201130230-965-377-329-49.70-259-126-10.20-134-445-12.70-88.30-49.506.00
Cashflow From Financing-188.3%-413-14352.00-206-838-69.90-308-368-62.0039.00-59.00-27441.0034.0024.00-58637.0034.00-23144.00-844
  Buy Backs157.1%4481748.0024986610035540697.002.001123030.001.009.00615-1.002566.00272

EW Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]   
Net sales$ 6,004.8$ 5,382.4$ 5,232.5
Cost of sales1,379.81,080.41,248.9
Gross profit4,625.04,302.03,983.6
Selling, general, and administrative expenses1,824.61,567.61,493.7
Research and development expenses1,071.8945.2903.1
Intellectual property agreement and litigation expense (Note 3)203.515.820.6
Change in fair value of contingent consideration liabilities (Note 12)(26.2)(35.8)(124.1)
Special charge and separation costs (Note 4)17.260.70.0
Operating income1,534.11,748.51,690.3
Interest expense17.619.218.4
Interest income(67.2)(35.5)(17.4)
Other income, net (Note 17)(14.4)(2.6)(12.7)
Income before provision for income taxes1,598.11,767.41,702.0
Provision for income taxes (Note 18)198.7245.5198.9
Net income1,399.41,521.91,503.1
Net loss attributable to noncontrolling interest(3.0)0.00.0
Net income attributable to Edwards Lifesciences Corporation.$ 1,402.4$ 1,521.9$ 1,503.1
Earnings per share attributable to Edwards Lifesciences Corporation:   
Basic (in dollars per share)$ 2.31$ 2.46$ 2.41
Diluted (in dollars per share)$ 2.30$ 2.44$ 2.38
Weighted-average number of common shares outstanding attributable to Edwards Lifesciences Corporation:   
Basic (in shares)606.7619.0623.3
Diluted (in shares)609.4624.2631.2

EW Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 1,144.0$ 769.0
Short-term investments (Note 7)500.5446.3
Accounts receivable, net of allowances of $8.3 and $7.9, respectively775.1643.0
Other receivables61.856.1
Inventories (Note 5)1,168.2875.5
Prepaid expenses146.8110.0
Other current assets239.3195.9
Total current assets4,035.73,095.8
Long-term investments (Note 7)583.91,239.0
Property, plant, and equipment, net (Note 5)1,749.41,632.8
Operating lease right-of-use assets (Note 6)94.092.3
Goodwill (Note 10)1,253.51,164.3
Other intangible assets, net (Note 10)428.4285.2
Deferred income taxes754.6484.0
Other assets463.7299.1
Total assets9,363.28,292.5
Current liabilities  
Accounts payable201.4201.9
Accrued and other liabilities (Note 5)969.1795.0
Operating lease liabilities (Note 6)24.925.5
Total current liabilities1,195.41,022.4
Long-term debt (Note 11)597.0596.3
Contingent consideration liabilities (Note 12)0.026.2
Taxes payable (Note 18)80.6143.4
Operating lease liabilities (Note 6)73.069.5
Uncertain tax positions (Note 18)339.3267.5
Litigation settlement accrual (Note 3)94.2143.0
Other liabilities264.3217.5
Total liabilities2,643.82,485.8
Commitments and contingencies (Notes 6, 11, and 19)
Stockholders' equity (Note 15)  
Preferred stock, $0.01 par value, authorized 50.0 shares, no shares outstanding0.00.0
Common stock, $1.00 par value, 1,050.0 shares authorized, 650.5 and 646.3 shares issued, and 601.1 and 608.3 shares outstanding, respectively650.5646.3
Additional paid-in capital2,274.41,969.3
Retained earnings8,992.47,590.0
Accumulated other comprehensive loss (Note 16)(242.8)(254.9)
Treasury stock, at cost, 49.4 and 38.0 shares, respectively(5,024.5)(4,144.0)
Total Edwards Lifesciences Corporation stockholders' equity6,650.05,806.7
Noncontrolling interest (Note 9)69.40.0
Total stockholders' equity6,719.45,806.7
Total liabilities and stockholders' equity$ 9,363.2$ 8,292.5
EW
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
 CEO
 WEBSITEwww.edwards.com
 EMPLOYEES17300

Edwards Lifesciences Corp Frequently Asked Questions


What is the ticker symbol for Edwards Lifesciences Corp? What does EW stand for in stocks?

EW is the stock ticker symbol of Edwards Lifesciences Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Edwards Lifesciences Corp (EW)?

As of Fri Feb 23 2024, market cap of Edwards Lifesciences Corp is 52.75 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EW stock?

You can check EW's fair value in chart for subscribers.

What is the fair value of EW stock?

You can check EW's fair value in chart for subscribers. The fair value of Edwards Lifesciences Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Edwards Lifesciences Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EW so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Edwards Lifesciences Corp a good stock to buy?

The fair value guage provides a quick view whether EW is over valued or under valued. Whether Edwards Lifesciences Corp is cheap or expensive depends on the assumptions which impact Edwards Lifesciences Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EW.

What is Edwards Lifesciences Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Feb 23 2024, EW's PE ratio (Price to Earnings) is 37.64 and Price to Sales (PS) ratio is 8.78. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EW PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Edwards Lifesciences Corp's stock?

In the past 10 years, Edwards Lifesciences Corp has provided 0.368 (multiply by 100 for percentage) rate of return.